Teikoku Pharma USA, a global pharmaceutical company, today announced positive topline results from its Phase 2 proof of concept study of TPU-006, a 4-day dexmedetomidine transdermal patch for Post Surgical Pain. The double-blind, placebo-controlled, single-dose study evaluated the analgesic efficacy and safety of TPU-006 after abdominoplasty surgery. A total of 167 patients had patches applied (either active or placebo).
Teikoku Pharma USA, a global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for TPU-006 in managing postoperative pain. TPU-006 is an investigational 4-day dexmedetomidine transdermal system, a novel drug delivery technology with a non-opioid active moiety for managing post-surgical pain.
Teikoku Pharma USA and Link Health Enter into License Agreement for Lidoderm® in China
SAN JOSE, Calif.,May 30, 2018--Teikoku Pharma USA Inc. (“TPU”) today announced that it has entered into an exclusive license agreement with Link Health Group LTD (“Link Health”) to develop market, sell, and distribute TPU’s flagship product, Lidoderm®, in China. Lidoderm® offers relief of the pain associated with post-herpetic neuralgia (“PHN”). It is a combination of lidocaine in a soft hydrogel plaster combining efficacious treatment with proven tolerability, safety and simple handling.
Teikoku Pharma USA Inc. (“TPU”) today announced that it has entered into an exclusive license agreement with Link Health Group LTD (“Link Health”) to develop market, sell, and distribute TPU’s flagship product, Lidoderm®, in China. Lidoderm® offers relief of the pain associated with post-herpetic neuralgia (“PHN”). It is a combination of lidocaine in a soft hydrogel plaster combining efficacious treatment with proven tolerability, safety and simple handling.
Teikoku Pharma USA Announces Positive Topline Results from Phase 2 Clinical Trial of TPU-006, Non Opioid Pain Management Patch in Bunionectomy Surgery
SAN JOSE, Calif., Aug. 22, 2017—Teikoku Pharma USA, Inc. (Teikoku Pharma) today announced positive topline results from its Phase 2 proof of concept study of TPU-006, a 3-day dexmedetomidine transdermal patch, a novel drug delivery system with a non-opioid active moiety for the management of post-surgical pain. The preliminary results demonstrate that the patch provides effective pain control across several parameters and produced no unexpected safety events in a postoperative setting.
SAN JOSE, Calif., September 6, 2016 -- Teikoku Pharma USA Inc. ("TPU") today announced that it has entered into an exclusive license agreement with Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (“Luoxin”) to market, sell and distribute TPU's Docetaxel Injection, Non-Alcohol Formula in China.
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals (“Eagle” or the “Company”) (NASDAQ:EGRX) today announced the shipment and commercial availability of Alcohol-Free Docetaxel Injection (“Docetaxel Injection”). Docetaxel Injection is approved for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.
San Jose, Calif., Teikoku Pharma USA (TPU) announced today that the U.S. Food and Drug Administration ("FDA") has approved Docetaxel Injection, Non-Alcohol Formula ("Docetaxel Injection") for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.
Teikoku Pharma USA Inc. (“TPU”) today announced that it has entered into an exclusive license agreement with Eagle Pharmaceuticals, Inc. to market, sell, and distribute TPU’s Docetaxel Injection, Non-Alcohol Formula in the United States.
Teikoku Pharma USA (TPU) announced today that it has submitted a 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Docetaxel Injection Concentrate, Non-Alcohol Formula on February 26, 2015 and received an acknowledgment of the receipt from FDA.